ABS Blog

New Castle, DE — November 14, 2024  —  ABS Bio, Inc., a leader in biospecimen sourcing, cell culture services and biostorage for the global pharmaceutical and biotechnology industry, today announced a strategic investment by 3 Boomerang Capital, a Greenwich, CT based healthcare-focused private equity firm. The investment will position ABS Bio to accelerate enhancements to its service offerings while growing its reach among biopharma R&D professionals.  ABS also announced an expanded board of directors, including John Chickosky as Executive Chairman, and Greg Swanberg and Martin LeBlanc as Directors.

The journey from initial drug discovery to clinical application is full of challenges, especially during the pre-clinical phase. This critical stage, where potential drug candidates are rigorously tested for efficacy and safety, is essential for identifying viable therapies before they reach human trials. Despite its importance, pre-clinical drug discovery is often hampered by various bottlenecks that can impede progress and inflate costs. In this blog, we will explore common bottlenecks in pre-clinical drug discovery, their impact, and potential strategies to overcome them.

The pharmaceutical industry is a dynamic and ever-evolving field, driven by innovation, scientific breakthroughs, and the pursuit of improved healthcare solutions. For scientists and professionals within the pharmaceutical and biotech sector, staying on top of the latest market trends, understanding the challenges, and foreseeing future prospects is essential for making informed decisions. In this blog, we will delve into the current state of the pharmaceutical market, highlighting key trends, addressing challenges, and offering insights into the promising future that lies ahead.

This post starts in very general terms and from a personal perspective. It moves on to more career and business-related topics. As you read this, I promise you that there will be something of value for you, your career, or your business. It ends with something that I hope is more personal for many of us.

In the dynamic world of pharmaceuticals and biotechnology, where groundbreaking discoveries and innovation are keys to success, scientists need dependable partners and resources to propel their research forward. Here at ABS, we offer a wide variety of solutions for scientists, helping them advance their projects and discoveries. In this blog, we will explore ABS’ offerings, and why it is a vital resource for scientists in the pharmaceutical and biotech sectors.

Efficiency is a cornerstone of success in the highly competitive and demanding fields of pharmaceuticals and biotechnology. Within laboratories, achieving and maintaining facility efficiency is essential to ensure that research and development processes run smoothly, deadlines are met, and resources are used optimally. In this article, we will explore why facility efficiency matters, focusing on key practices like implementing the 5S methodology, ensuring each hood has its own supplies, and the benefits they bring to scientists in these industries.  

Another year comes rapidly to a close. 2023 was a year of accelerating changes. It is likely that 2024 will bring even more transformation in how we live and work. AI and other technologies will hasten the pace.  

Let’s begin with a few questions. What are your goals and those of your organization? Is it to grow cells? Is it to find and acquire human biospecimens? Is it to inventory and store biological samples? These tasks are important, but they are not your mission or the value proposition of your organization. 

ABS’ Mission is to save and improve lives by making the discovery of drugs and diagnostics faster, easier, and more reliable. Our mission is to make your Mission more successful. As an extension of our mutual mission, we have founded the ABS BioAccelerator to speed up the success of growing life science companies. 

ABS typically works with most of the world’s major pharmaceutical and biotechnology companies. As a small business, we know how difficult growth can be. Far too many companies fail, especially in the early stages.